Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child

Pediatr Blood Cancer. 2009 Sep;53(3):468-71. doi: 10.1002/pbc.22067.

Abstract

An 11-year-old female developed heparin induced thrombocytopenia (HIT) with thrombosis during therapy for lower extremity deep vein thrombosis and pulmonary embolism. Transition from bivalirudin, a direct thrombin inhibitor (DTI), to warfarin resulted in extensive re-thrombosis, and fondaparinux therapy similarly failed. She was then treated with argatroban, and transitioned successfully to warfarin after 9 weeks. The risk of re-thrombosis was ultimately reduced by allowing time for the thrombogenic potential to abate. The argatroban/warfarin transition was monitored with chromogenic factor X levels. This case highlights several difficult problems in pediatric thrombosis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects*
  • Child
  • Female
  • Fondaparinux
  • Heparin / adverse effects*
  • Humans
  • Polysaccharides / adverse effects*
  • Thrombocytopenia / chemically induced*
  • Thrombosis / chemically induced*
  • Warfarin / adverse effects*

Substances

  • Anticoagulants
  • Polysaccharides
  • Warfarin
  • Heparin
  • Fondaparinux